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Abstract
Background: Locoregional recurrence (LRR) is an important factor after pancreaticoduode-
nectomy (PD) for pancreatic cancer. IORT administered to the resection bed may improve local 
tumor control. 
Methods: We performed a retrospective analysis of patients who underwent PD at Thomas 
Jefferson University Hospital (TJUH) between 1995 and 2005 to identify patients who underwent 
resection with and without intraoperative radiation therapy (IORT). Data collected included age, 
gender, complications, margin status, stage, survival, and recurrence. Unadjusted analyses of 
the IORT and non-IORT groups were performed using Fisher’s chi-square method for discrete 
variables and Wilcoxon Rank Sum test for continuous variables. To account for biases in patient 
selection for IORT, a propensity score was calculated for each patient and adjusted statistical 
analyses were performed for survival and recurrence outcomes. 
Results: Between January 1995 and November 2005, 122 patients underwent PD for perimpullary 
tumors, including 99 pancreatic cancers. Of this group, 37 patients were treated with IORT, and 
there was adequate follow-up information for a group of 46 patients who underwent PD without 
IORT. The IORT group contained a higher percentage of Stage IIB or higher tumors (65%) 
than in the non-IORT group (39.1%), though differences in stage did not reach significance 
(p = 0.16). There was a non-significant decrease in the rate of LRR in patients who had IORT (39% 
non-IORT vs. 23% IORT, p = 0.19). The median survival time of patients who received IORT was 
19.2 months, which was not significantly different than patients managed without IORT, 21.0 
months (p=0.78). In the propensity analyses, IORT did not significantly influence survival or 
recurrence after PD. 
Conclusions: IORT can be safely added to management approaches for resectable pancreatic 
cancer, with acceptable morbidity and mortality. IORT did not improve loco-regional control and 
did not alter survival for patients with resected pancreatic cancer. IORT is an optional component 
of adjuvant chemoradiation for pancreatic cancer. In the future, IORT may be combined with 
novel therapeutic agents in the setting of a clinical trial in order to attempt to improve outcomes 
for patients with pancreatic cancer.
Surgical resection is an essential component 
in the therapeutic approach to patients with 
localized pancreatic cancer. Despite refine-
ments in surgical technique, local and distant 
recurrences are common. Long-term survival 
rates are low for patients with resectable 
tumors, with 15-20% 5-year survival reported 
among patients who undergo pancreatico-
duodenectomy (PD) alone.1, 2 In a review of 
resection margins of 72 patients who under-
went PD, Willett et al. detected a positive mar-
gin in 51% of cases; this factor was associated 
with inferior survival and local control when 
compared with those patients with negative 
surgical margins.2 Although there is controversy 
regarding the appropriate components of 
adjuvant management of resected pancreatic 
cancer,3-7 outcomes achieved after surgery 
alone continue to be poor; therefore, the need 
remains for adjuvant therapy to improve local 
control and survival.3-8 In the United States, 
adjuvant chemoradiotherapy (CRT) is performed 
as part of the standard therapeutic paradigm, 
based on the recurrence patterns of pancreatic 
cancer after surgery.8, 9
Intraoperative radiation therapy (IORT), the 
delivery of a single, large dose of irradiation at 
the time of surgery, was developed in order 
to administer higher doses of irradiation while 
displacing or shielding adjacent normal tissue 
structures from radiation exposure .10 In pancreatic 
cancer, IORT has been offered for unresect-
able tumors to provide local tumor control 
and palliation of pain,11-16 and for resectable 
tumors in an effort to improve local control 
and survival after PD.11-19 Although a definitive 
survival benefit has not been observed, 
improvement of local control by IORT at the 
time of PD for resectable pancreatic cancer is
supported by retrospective data, as well as by a 
prospective, randomized trial conducted at the 
National Cancer Institute (NCI).19-21
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At our institution, IORT has been offered since 1986 in a dedicated 
operating suite located in the radiotherapy department for patients with 
either resectable or unresectable pancreatic cancer. IORT was considered for 
all patients undergoing PD at our institution until 1998. Since then, IORT 
has been reserved for patients with larger tumors with higher risk of 
positive margins, as visualized by the surgeon on preoperative imaging. 
Prior reports from our institution have described outcomes of patients 
who received IORT for resectable and unresectable pancreatic cancer 
prior to 1995.13, 22 The current study evaluates outcomes for patients who 
received treatment for resectable pancreatic cancer from 1995 to 2005. 
As a result of physician bias for the use of IORT in more advanced-
stage pancreatic cancer at our institution, it was not possible to identify 
a comparative group of patients for use in a matched pair analysis. 
Therefore, in order to account for the biases inherent in the nonrandom 
treatment assignment for patients in the current study, analyses of
survival and recurrence were adjusted using propensity scoring.23 In this 
way, we attempted to minimize the influence of confounding patient- 
and tumor-related variables in order to assess the contribution of 
IORT to local tumor control and survival of patients with localized, 
resectable pancreatic cancer treated at our institution. 
Materials & Methods
A prospective tumor registry database was searched to identify all 
patients who underwent PD at Thomas Jefferson University during 
1995-2005. The study was performed with approval of the institutional 
review board at Thomas Jefferson University. These patients were 
further divided into those who did and did not receive IORT. We
collected data regarding age, gender, margin status, stage, survival and 
recurrence. Loco-regional recurrence (LRR) was defined as recurrence 
within the tumor bed or regional lymph nodes. Systemic recurrence 
(SR) consisted of recurrence in the liver, peritoneum, lungs, bone, or 
other distant site. Overall survival (OS) and time to LRR were measured 
from the date of surgery. Given the institutional bias towards IORT for 
larger tumors during much of the study period, a difference between 
treatment groups was anticipated in the statistical analysis. A propensity 
score, a statistical method to adjust for nonrandom treatment decisions 
in observational studies, was also calculated for each patient using a 
logistic regression model.23 
Treatment Policy
All patients were treated according to institutional treatment policies 
during 1995-2005. As a general rule, IORT was considered for all 
patients prior to 1998 and subsequently for patients with larger tumors 
based on review of preoperative imaging by the attending surgeon. For 
these patients, surgery was performed in an operating room located 
in the radiation oncology department, an arrangement selected to 
facilitate IORT delivery. IORT was delivered using 6-15 MeV electrons 
and cone sizes selected in order to deliver a dose of 10-20 Gy to a field 
encompassing the pancreatic tumor bed within the 90% isodose line. 
Regional lymph nodes were not included in the target volume for 
most cases. The cone size, treatment set-up, and immobilization were 
selected in order to treat the target volume while minimizing exposure 
of adjacent normal tissue structures. The standard dose, 15 Gy, was 
reduced to 10 Gy for either large treatment volumes or margins that 
were clearly negative. For larger tumors, 20 Gy was often prescribed. 
In cases where adjuvant external beam radiation therapy (RT) was 
also delivered, a dose of 45-50.4 Gy was prescribed using a conformal, 
four-field radiation technique.
Statistical Analysis
Simple descriptive statistics were generated, and unadjusted associations 
with IORT were determined using Fisher’s Chi Square test for categorical 
variables and using the Wilcoxon rank sum test for continuous variables. 
The propensity score, which was calculated for all patients included in 
the analysis using a logistic regression model, included resection status, 
AJCC Stage, differentiation, age, race, and sex. Propensity scores were 
incorporated as a categorical variable in the statistical analyses based 
on quartiles. The association of IORT with the primary outcome of 
survival was determined using a Cox proportional hazards model. 
The Cox proportional hazards model included IORT, the propensity 
score (by quartile), adjuvant chemotherapy, and adjuvant radiotherapy. 
Association of IORT with the secondary outcomes of any recurrence, 
loco-regional recurrence, and systemic recurrence was determined using 
logistic regression models. Included in the logistic regression models for 
adjusted analyses of recurrence were IORT, the propensity score (by 
quartile), adjuvant chemotherapy, and adjuvant radiotherapy.
Results
From January 1995 to November 2005, 122 patients underwent PD for 
periampullary tumors, including 99 pancreatic cancers. We identified 
37 patients with pancreatic cancer who were treated with IORT. Among 
the remaining 62 patients with pancreatic cancer treated without IORT, 
adequate follow-up data could be obtained for 46 patients, who comprised 
the non-IORT group used in the statistical analyses. The median patient 
age in the IORT group was 64 years (inter-quartile range, 55-70 years); in 
the non-IORT group, the median age was 67 years (inter-quartile range, 
59-74 years). The IORT group demonstrated non-significant trends 
toward more advanced stage tumors (p=0.16) and a higher rate of positive 
margins (p=0.26). A higher proportion of patients received adjuvant 
chemotherapy after PD with IORT than after PD alone (p=0.05) (Table 1). 
There were 2 perioperative deaths in the IORT group (5.4%) and none in 
the non-IORT group (p=0.20). Rates of perioperative complications were 
similar, 46% in the IORT group versus 40% in the non-IORT group. The 
median follow-up among surviving patients was 21 months. 
Recurrence and Survival
Recurrence data were available for 80% of all patients, including 30 IORT 
patients (81%) and 36 non-IORT patients (78%). Rates of loco-regional 
recurrence (LRR) (Figure 1) or any recurrence (Figure 2) were not 
significantly different between the IORT and non-IORT groups. Among 
non-IORT patients, there was loco-regional recurrence (LRR) in 39%, 
systemic recurrence (SR) in 50%, and any recurrence in 69%. In the 
IORT group, LRR in 23%, SR in 57% of patients, with, and recurrence 
was observed in 67% (Table 2). Liver metastases were the most common 
form of SR. LRR in the absence of SR was observed in 2 patients (7%) 
in the IORT group and in 7 patients in the non-IORT group (19%). LRR 
was not significantly different between the IORT and non-IORT groups 
(p=0.20). The median survival time of patients undergoing IORT was 
19.2 months, which was not significantly different than patients man-
aged without IORT, 21.0 months (p=0.49) (Figure 3). 
Propensity Score Analysis
In the adjusted, propensity score analysis of the association of IORT 
with survival, IORT was not associated with significant improvement of 
survival time (Table 3). The Cox regression model for survival included
IORT status with propensity score (by quartile), as well as adjuvant RT and 
chemotherapy. The propensity score-adjusted analyses of the association 
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of IORT with LRR, with SR, and with any recurrence were conducted 
using logistic regression models (Table 4). After adjusting for propensity 
score quartile and for adjuvant therapies, IORT did not influence recur-
rence rates after PD for pancreatic cancer. A non-significant trend towards 
higher rates of any recurrence was noted for propensity scores in the third 
(OR 9.66, p = 0.14) or fourth quartile (OR 9.64, p = 0.15).
Discussion
Local control was not significantly different between the two groups, 
IORT and non-IORT, evaluated in the current series. Although the 
current study is limited by its retrospective design and institution bias 
towards treating more advanced tumors with IORT, an attempt was 
made to account for nonrandom allocation of patients into the IORT 
and non-IORT groups by using propensity score values in adjusted 
statistical analyses of the association of IORT with survival and recurrence. 
Adjuvant chemotherapy was administered to more patients in the 
IORT group. Although information concerning decision-making was 
not available, the increased rate of chemotherapy may be related to the 
presence of more advanced tumors in the IORT group. Despite the trends 
toward more advanced-stage tumors and positive resection margins in 
the IORT group, similar local control rates were observed. 
The disparities in stage and margin status in the current study may have 
obscured any potential local control benefit of IORT, as these factors have 
been reported to negatively influence survival for patients with resected 
pancreatic cancer.24, 25 Prior retrospective, single-institution reports 
suggest that IORT improves local control after PD by approximately 
30%.19, 21 In this study, LRR was 50% less in the IORT group. In the 
prospective, randomized trial conducted at the NCI, local control 
improved from 0% to 33% with the addition of IORT.20 In a recent series 
Table 1. Tumor- and treatment-related characteristics for 
37 IORT patients and 46 non-IORT patients with resected 
pancreatic cancer.  
Factor PD + IORT[n (%)]
PD (No IORT) 
[n (%)] p value
Stage
I
IIA 
≥IIB
7 (19)
6 (16)
24 (65)
16 (35)
12 (26)
18 (39)
0.16
Margin Status
RO
R1/R2
21 (57)
16 (43)
32 (70)
14 (30)
0.26
Grade 
(n=81)
Well
Moderate
Poor
7 (19)
21 (58)
8 (22)
8 (18)
25 (56)
12 (27)
0.91
Adjuvant 
Chemotherapy
(n=79)
Yes
No
26 (84)
5 (16)
27 (63)
16 (37)
0.05
Adjuvant EBRT
(n=75)  
Yes
No
23 (74)
8 (26)
29 (66)
15 (34)
0.44
1.0
0.6
0.2
0.8
0.4
400
Time to Recurrence (months)
305 20 3510 2515
Treated with IORT
Treated without IORT
p = 0.20
Figure 1. Kaplan-Meier plot of locoregional failure for patients 
treated with (solid line) and without (dashed line) IORT (p = 0.20).
Table 2. Location of first recurrence. Thirty patients in the IORT 
group and 36 patients in the non-IORT group were included in 
the recurrence analysis, based on availability 
of data to determine site of recurrence.
Site of First Recurrence PD + IORT
[n (%)]
PD (No-IORT)
[n (%)]
Locoregional 7 (23) 14 (39)
 Tumor Bed 6 (20) 8 (22)
 Lymph Node 4 (13) 10 (28)
 Locoregional-Only 2 (7) 7 (19)
Systemic 17 (57) 18 (50)
 Liver 11 (37) 11 (31)
 Lung/Pleura 4 (13) 7 (19)
 Systemic-Only 14 (47) 11 (31)
1.0
0.6
0.2
0.8
0.4
Treated with IORT
Treated without IORT
p = 1.0
400
Time to Recurrence (months)
305 20 3510 2515
Figure 2. Kaplan-Meier plot of recurrence (any site) for patients 
treated with (solid line) and without (dashed line) IORT (p = 1.0).
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from the City of Hope National Medical Center, isolated local recur-
rences were reduced from 33% to 5% with the addition of IORT, which 
is comparable to the rate of isolated LRR in the current report (7%).24 
Reni et al. reported a similar alteration of recurrence patterns, with 15% 
local-only recurrences with IORT versus 33% without IORT.26 The 
cumulative evidence, including one prospective randomized trial and a 
few prospective studies, supports a local control benefit for IORT in
resectable pancreatic cancer. An improvement in local control has not 
been shown to translate into a clinical benefit in survival outcomes, 
including in this study. Although a propensity score analysis was
performed in the current study to evaluate the influence of IORT on 
recurrence rates after PD, the limited size of the patient population may 
have restricted our ability to detect a significant positive effect. 
The survival rates were not different between the IORT and non-IORT 
groups in the current series, which is consistent with the results of 
the prospective NCI study.20 Given the propensity of pancreatic cancer 
towards distant metastatic recurrence, it is not surprising that a measurable 
increase in local control did not produce a corresponding improvement 
of survival.27 Although some authors report a survival benefit 
from IORT for resectable pancreatic tumors at their institutions, the 
literature  does not consistently support this claim, and detection of a potential small survival benefit would require a large trial.19, 22, 24, 26, 28, 29 
Regardless of the absence of improved survival, the problem of 
locoregional control does leave open a place for radiation therapy after 
PD, and IORT is an effective technique to boost radiation dose around 
the resection bed while displacing sensitive adjacent organs.8, 10, 17, 30 A 
recent analysis of the Surveillance, Epidemiology, and End Results data-
base revealed a survival benefit to the addition of adjuvant radiotherapy 
after PD, and radiation therapy remains an important component of 
adjuvant strategies in the United States.25 Results recently published 
from the Radiation Therapy Oncology Group (RTOG) trial 9704, the 
first cooperative group study to require prospective quality assurance of 
radiotherapy, suggest a benefit to the addition of gemcitabine to adjuvant 
CRT after PD. The rates of first relapse in local and regional sites in the 
experimental arm of RTOG 9704 were 23% and 7%, respectively..31 
Importantly, the addition of IORT after PD did not increase peri-
operative complication rates significantly in the current series, which is 
consistent with the earlier experience from our institution.22 Although 
late complications have been reported after IORT for pancreatic cancer, 
our results and other reports suggest that IORT may be delivered 
safely in combination with surgical resection.24, 26, 28, 32, 33-37 Selection of 
Table 2. Location of first recurrence.  Thirty patients in 
the IORT group and 36 patients in the non-IORT group were 
included in the recurrence analysis, based on availability 
of data to determine site of recurrence.
Site of First Recurrence PD + IORT
[n (%)]
PD (No-IORT)
[n (%)]
Locoregional 7 (23) 14 (39)
 Tumor Bed 6 (20) 8 (22)
 Lymph Node 4 (13) 10 (28)
 Locoregional-Only 2 (7) 7 (19)
Systemic 17 (57) 18 (50)
 Liver 11 (37) 11 (31)
 Lung/Pleura 4 (13) 7 (19)
 Systemic-Only 14 (47) 11 (31)
Table 3. Cox proportional survival hazard model for 
the association of IORT, propensity score, and other 
factors with survival time in months.
Estimate
Standard
Error Chi-Square
Hazard 
Ratio p
IORT    -0.34 0.35 0.94 0.71 0.33
Adjuvant 
Chemo-
therapy
0.51 0.73 0.48 1.66 0.49
Adjuvant 
Radiotherapy
-1.05 0.68 2.39 0.35 0.12
Propensity Score (vs. 1st Quartile)
2nd Quartile
3rd Quartile
4th Quartile
   -0.68
0.55
0.58
0.45
0.49
0.47
2.35
1.26
1.56
0.50
1.73
1.79
0.13
0.26
0.21
Table 4. Logistic regression models of the association of IORT, 
propensity score, and other factors, with the outcomes of any 
recurrence, locoregional occurrence, and systemic recurrence.
Odds Ratio 95% CI p
Any Recurrence
IORT 0.77 (0.19, 5.20) 0.72
Adjuvant Chemotherapy 1.69 (0.15, 19.29) 0.67
Adjuvant Radiotherapy 1.11 (0.11, 11.68) 0.93
Propensity Score (vs. 1st Quartile)
2nd Quartile
3rd Quartile
4th Quartile
1.22
9.66
9.64
(0.33, 4.52)
(0.47, 197.40)
(0.46, 203.31)
0.76
0.14
0.15
Locoregional Recurrence
IORT 0.41 (0.10, 10.30) 0.23
Adjuvant Chemotherapy 0.49 (0.02, 11.37) 0.65
Adjuvant Radiotherapy 1.74 (0.86, 35.51) 0.72
Propensity Score (vs. 1st Quartile)
2nd Quartile
3rd Quartile
4th Quartile
0.39
5.13
3.32
(0.02, 7.47)
(0.73, 36.03)
(0.46, 23.93)
0.53
0.10
0.23
Systemic Recurrence
IORT 0.99 (0.28, 3.52) 0.99
Adjuvant Chemotherapy 0.40 (0.03, 6.42) 0.52
Adjuvant Radiotherapy 1.30 (0.10, 16.96) 0.84
Propensity Score (vs. 1st Quartile)
2nd Quartile
3rd Quartile
4th Quartile
1.11
0.91
0.59
(0.23, 5.40)
(0.16, 5.13)
(0.10, 3.50)
0. 90
0.91
0.56
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radiation doses for IORT was influenced by seminal, preclinical canine 
experiments performed at the National Cancer Institute that provided 
an understanding of normal tissue tolerances, including surgically-
manipulated tissues, for IORT.38,39 These studies created a foundation for 
the rational delivery of IORT in humans, so it should not be surprising 
that clinical studies have shown these RT doses to be safe and feasible.
Based on recent practice changes at our institution, IORT will be offered 
infrequently for patients with localized pancreatic tumors, in favor of 
alternate adjuvant strategies after surgical resection. Novel adjuvant 
therapy combinations tested in recent institutional and cooperative 
group trials have focused on systemic treatments aimed at reducing 
metastatic recurrences after PD, as distant dissemination is a dominant 
cause of mortality for patients with pancreatic cancer.27, 40 However, 
adjuvant external beam radiation therapy remains an important
component of management, based on recognition of the parallel 
importance of preventing local recurrence.2, 25 Although the current 
study does not support its continued use, it is reasonable that IORT is 
considered as a potential component of adjuvant RT strategies. Should 
adjuvant systemic therapies for resected pancreatic cancer improve in the 
future, LRR may become a more significant concern. IORT may become a 
more important tool for maximizing loco-regional control in that situation. 
In summary, the current study demonstrates that IORT is a safe addition 
to PD and standard adjuvant therapies, with the intention of improving 
local control after PD for patients with resectable pancreatic cancer. 
Although local control was not significantly improved with the addition 
of IORT in the current study, the significantly higher number of more 
advanced stage tumors and a trend towards more positive surgical margins 
in the IORT patients may have influenced the results of our comparative 
analyses. We cannot currently recommend routine use of IORT in the 
adjuvant setting for patients with resected pancreatic cancer. Future clinical 
trials with novel therapeutic agents may include IORT in combination 
with resection, adjuvant external beam radiotherapy, and systemic agents
in order to improve outcomes for patients with pancreatic cancer. 
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